Patents by Inventor Mark L. Boys
Mark L. Boys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9938289Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: January 14, 2016Date of Patent: April 10, 2018Assignee: FBM THERAPEUTICS, LLCInventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Publication number: 20160200735Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: ApplicationFiled: January 14, 2016Publication date: July 14, 2016Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Patent number: 9260450Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: March 3, 2015Date of Patent: February 16, 2016Assignee: THESAN PHARMACEUTICALS, INC.Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Patent number: 9090625Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: April 17, 2013Date of Patent: July 28, 2015Assignee: THESAN PHARMACEUTICALS, INC.Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Publication number: 20150175624Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: ApplicationFiled: March 3, 2015Publication date: June 25, 2015Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Publication number: 20140031385Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: ApplicationFiled: April 17, 2013Publication date: January 30, 2014Applicant: Medicis Phamaceutical CorporationInventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Patent number: 8455512Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: May 20, 2011Date of Patent: June 4, 2013Assignee: Medicis Pharmaceutical CorporationInventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Publication number: 20110224251Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: ApplicationFiled: May 20, 2011Publication date: September 15, 2011Applicant: Graceway Pharmaceuticals, LLCInventors: Stephen D. Barrett, Mark L. Boys, Huifen Chen, James B. Kramer
-
Patent number: 7964612Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: October 12, 2007Date of Patent: June 21, 2011Assignee: Graceway Pharmaceuticals, LLCInventors: Stephen D. Barrett, James B. Kramer, Mark L Boys, Huifen Chen
-
Patent number: 7670613Abstract: The present invention is directed to a new class of 4-cycloalkoxy benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.Type: GrantFiled: July 5, 2005Date of Patent: March 2, 2010Assignee: Pfizer Inc.Inventors: Lain-Yen Hu, Bruce A. Lefker, Daniel Y. Du, Yvonne Dorothy Smith, Huangshu Lei, William Glen Harter, Victoria Leigh Downs, Mark L. Boys, Donna Michele Iula
-
Publication number: 20100048517Abstract: The present invention is directed to a new class of 4-cycloalkoxy benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.Type: ApplicationFiled: November 5, 2009Publication date: February 25, 2010Inventors: Lain-Yen Hu, Bruce A. Lefker, Daniel Y. Du, Yvonne Dorothy Smith, Huangshu Lei, William Glen Harter, Victoria Leigh Downs, Mark L. Boys, Donna Michele Iula
-
Patent number: 7119098Abstract: The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively antagonizing the ???3 and/or the ???5 integrin without significantly antagonizing the IIb/IIIa integrin.Type: GrantFiled: June 15, 2001Date of Patent: October 10, 2006Assignee: Pharmacia CorporationInventors: Srinivasan Raj Nagarajan, Ish Kumar Khanna, Michael B. Tollefson, Scott B. Mohler, Barbara B. Chen, Mark Russell, Balekudru Devadas, Thomas D. Penning, Lori A. Schretzman, Dale P. Spangler, Mark L. Boys, Nizal S. Chandrakumar, Hwang-Fun Lu
-
Patent number: 7115596Abstract: The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the ?v?3 and/or the ?v?5 integrin without significantly inhibiting the ?v?6 integrin.Type: GrantFiled: December 19, 2003Date of Patent: October 3, 2006Assignee: Pharmacia CorporationInventors: John A. Wendt, Heather Stenmark, Hongwei Wu, Yaping Wang, Barbara B. Chen, Thomas D. Penning, Victoria L. Downs, Mark L. Boys, Mark Russell, Dale P. Spangler
-
Publication number: 20040092497Abstract: The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively antagonizing the &agr;&ngr;&bgr;3 and/or the &agr;&ngr;&bgr;5 integrin without significantly antagonizing the IIb/IIIa integrin.Type: ApplicationFiled: September 5, 2003Publication date: May 13, 2004Inventors: Srinivasan Raj Nagarajan, Ish Kumar Khanna, Michael B. Tollefson, Scott B, Mohler, Barbara B. Chen, Mark Russell, Balekudru Devadas, Thomas D. Penning, Lori A. Schretzman, Dale P. Spangler, Mark L. Boys, Nizal S. Chandrakumar, Hwang-Fun Lu
-
Publication number: 20040043994Abstract: The present invention relates to a class of compounds represented by the Formula I.Type: ApplicationFiled: January 21, 2003Publication date: March 4, 2004Inventors: Ish Kumar Khanna, Yi Yu, Hwang-Fun Lu, Nizal S. Chandrakumar, Renee M. Huff, Mark Russell, Mark L. Boys, Lori A. Schretzman, Barbara B. Chen, Bipinchandra N. Desai, Srinivasan Raj Nagarajan, Alan F. Gasiecki, Thomas D. Penning, Thomas Rogers, John Adam Wendt, Albert Khilevich, Yaping Wang
-
Patent number: 6531494Abstract: The present invention relates to a class of compounds represented by the Formula I. or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr;V&bgr;3 and/or the &agr;V&bgr;5 integrin.Type: GrantFiled: August 29, 2001Date of Patent: March 11, 2003Assignee: Pharmacia CorporationInventors: Ish Kumar Khanna, Yi Yu, Balekudru Devadas, Hwang-Fun Lu, Nizal S Chandrakumar, Renee M. Huff, Bipinchandra N. Desai, Srinivasan Raj Nagarajan, Alan F. Gasiecki, Thomas D. Penning, Mark A. Russell, Mark L. Boys, Lori A. Schretzman, Barbara B. Chen, Thomas Rogers, John Adam Wendt, Albert Khilevich, Yaping Wang
-
Patent number: 5631399Abstract: The present invention relates to a novel process for the preparation of ethyl 3S-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentyno ate and pharmaceutically acceptable acid addition salt thereof.Type: GrantFiled: May 14, 1996Date of Patent: May 20, 1997Assignee: G. D. Searle & Co.Inventors: Kevin A. Babiak, Srinivasan Babu, James R. Behling, Mark L. Boys, Kimberly J. Cain-Janicki, Wendel W. Doubleday, Payman Farid, Timothy J. Hagen, E. A. Hallinan, Donald W. Hansen, Jr., Donald E. Korte, Kathleen T. Mc Laughlin, John R. Medich, Sean T. Nugent, Vlasdislav Orlovski, Jung M. Park, Karen B. Peterson, Daniel R. Pilipauskas, Barnett S. Pitzele, Sofya Tsymbalov, Glenn L. Stahl
-
Patent number: 5536869Abstract: The present invention relates to a novel process for the preparation of ethyl 3S-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentyno ate and pharmaceutically acceptable acid addition salt thereof which comprises treating (trimethylsilyl)acetylene sequentially with n-butyllithium and 4-formylmorpholine followed by acid hydrolysis to give 3-(trimethylsilyl)-2-propynal; treating 3-(trimethylsilyl)-2-propynal with lithium bis(trimethylsilyl)amide to give in situ N,3-bis(trimethylsilyl)-2-propyn-1-imine; condensation of N,3-bis(trimethylsilyl)-2-propyn-1-imine with lithium t-butyl acetate to give (.+-.)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate; treating (.+-.)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate- with p-toluenesulfonic acid to give (.+-.)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate, mono p-toluenesulfonic acid salt, treatment of resulting salt with ethanol in the presence of p-toluenesulfonic acid to give (.+-.Type: GrantFiled: July 14, 1995Date of Patent: July 16, 1996Assignee: G. D. Searle & Co.Inventors: Kevin A. Babiak, Srinivasan Babu, James R. Behling, Mark L. Boys, Kimberly J. Cain-Janicki, Wendel W. Doubleday, Payman Farid, Timothy J. Hagen, E. Ann Hallinan, Donald W. Hansen, Jr., Donald E. Korte, Kathleen T. McLaughlin, John R. Medich, Sean T. Nugent, Vlasdislav Orlovski, Jung M. Park, Karen B. Peterson, Daniel R. Pilipauskas, Barnett S. Pitzele, Sofya Tsymbalov, Glenn L. Stahl